Christina Ackermann - May 5, 2022 Form 4 Insider Report for Bausch & Lomb Corp (BLCO)

Role
Officer
Signature
/s/ Debra E. Levin, attorney-in-fact
Stock symbol
BLCO
Transactions as of
May 5, 2022
Transactions value $
$0
Form type
4
Date filed
5/9/2022, 06:46 PM
Previous filing
Mar 11, 2022
Next filing
Jun 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLCO Common Shares, No Par Value Award $0 +83.3K $0.00 83.3K May 5, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLCO Non-Qualified Stock Options (right to purchase) Award $0 +330K $0.00 330K May 5, 2022 Common Shares, No Par Value 330K $18.00 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the grant of restricted stock units ("RSUs") under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the "Plan"). Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch + Lomb Corporation (the "Company").
F2 Reflects the grant of stock options to purchase Common Shares under the Plan.
F3 The stock options are generally scheduled to vest and become exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the terms of the applicable award agreement.
F4 The stock options will expire on the tenth anniversary of the grant date.

Remarks:

The Reporting Person's title as an officer of the Issuer is Executive Vice President & General Counsel and President, Ophthalmic Pharmaceuticals.